152 related articles for article (PubMed ID: 29121104)
1. Evaluation of the major changes in eighth edition of the American Joint Committee on Cancer pathological staging for prostate cancer treated with prostatectomy.
Xiao WJ; Zhu Y; Dai B; Ye DW
PLoS One; 2017; 12(11):e0187887. PubMed ID: 29121104
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of clinical staging of the American Joint Committee on Cancer (eighth edition) for prostate cancer.
Xiao WJ; Zhu Y; Zhu Y; Dai B; Ye DW
World J Urol; 2018 May; 36(5):769-774. PubMed ID: 29372356
[TBL] [Abstract][Full Text] [Related]
3. Ability of the 1992 and 1997 American Joint Committee on Cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease.
Han M; Walsh PC; Partin AW; Rodriguez R
J Urol; 2000 Jul; 164(1):89-92. PubMed ID: 10840430
[TBL] [Abstract][Full Text] [Related]
4. [The 1992 TNM classification of T2 prostate cancer predicts pathologic stage and prognosis better than the revised 1997 classification].
Koh H; Maru N; Muramoto M; Wheeler TM; Scardino PT; Ohori M
Nihon Hinyokika Gakkai Zasshi; 2002 Jul; 93(5):595-601. PubMed ID: 12174634
[TBL] [Abstract][Full Text] [Related]
5. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
6. Outcome evaluation of the 1997 American Joint Committee on Cancer staging system for prostate carcinoma treated by radiation therapy.
Iyer RV; Hanlon AL; Pinover WH; Hanks GE
Cancer; 1999 Apr; 85(8):1816-21. PubMed ID: 10223577
[TBL] [Abstract][Full Text] [Related]
7. The results of radical prostatectomy at a community hospital during the prostate specific antigen era.
Smitt MC; Heltzel M
Cancer; 1996 Mar; 77(5):928-33. PubMed ID: 8608486
[TBL] [Abstract][Full Text] [Related]
8. Percent tumor volume vs American Joint Committee on Cancer staging system subclassification for predicting biochemical recurrence in patients with pathologic T2 prostate cancer.
Choi SY; Chi BH; Lim B; Kyung YS; You D; Jeong IG; Song C; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2020 Feb; 146(2):537-543. PubMed ID: 31915914
[TBL] [Abstract][Full Text] [Related]
9. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.
Caster JM; Falchook AD; Hendrix LH; Chen RC
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):244-51. PubMed ID: 25841621
[TBL] [Abstract][Full Text] [Related]
10. Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate.
Dess RT; Suresh K; Zelefsky MJ; Freedland SJ; Mahal BA; Cooperberg MR; Davis BJ; Horwitz EM; Terris MK; Amling CL; Aronson WJ; Kane CJ; Jackson WC; Hearn JWD; Deville C; DeWeese TL; Greco S; McNutt TR; Song DY; Sun Y; Mehra R; Kaffenberger SD; Morgan TM; Nguyen PL; Feng FY; Sharma V; Tran PT; Stish BJ; Pisansky TM; Zaorsky NG; Moraes FY; Berlin A; Finelli A; Fossati N; Gandaglia G; Briganti A; Carroll PR; Karnes RJ; Kattan MW; Schipper MJ; Spratt DE
JAMA Oncol; 2020 Dec; 6(12):1912-1920. PubMed ID: 33090219
[TBL] [Abstract][Full Text] [Related]
11. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of subclassification (pT2 stage) of pathologically organ-confined prostate cancer: Confirmation of the changes introduced in the 8th edition of the American Joint Committee on Cancer (AJCC) staging system.
Antunes HP; Parada B; Carvalho J; Eliseu M; Jarimba R; Oliveira R; Tavares-da-Silva E; Figueiredo A
Arch Ital Urol Androl; 2018 Sep; 90(3):191-194. PubMed ID: 30362685
[TBL] [Abstract][Full Text] [Related]
13. The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA < or = 10 ng/ml and T1c,2a: implications for patient selection for prostate-only therapy.
D'Amico AV; Renshaw AA; Schultz D; Rocha S; Richie JP
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):847-51. PubMed ID: 10571188
[TBL] [Abstract][Full Text] [Related]
14. Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer.
Preisser F; Marchioni M; Nazzani S; Bandini M; Tian Z; Saad F; Pompe RS; Briganti A; Budäus L; Montorsi F; Huland H; Graefen M; Tilki D; Karakiewicz PI
Eur Urol Oncol; 2018 Jun; 1(2):160-168. PubMed ID: 31100241
[TBL] [Abstract][Full Text] [Related]
15. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
[TBL] [Abstract][Full Text] [Related]
16. Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification.
Bhindi B; Karnes RJ; Rangel LJ; Mason RJ; Gettman MT; Frank I; Tollefson MK; Lin DW; Thompson RH; Boorjian SA
J Urol; 2017 Dec; 198(6):1286-1294. PubMed ID: 28669765
[TBL] [Abstract][Full Text] [Related]
17. Optimizing patient selection for prostate monotherapy.
Lee AK; Schultz D; Renshaw AA; Richie JP; D'Amico AV
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):673-7. PubMed ID: 11172948
[TBL] [Abstract][Full Text] [Related]
18. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
[TBL] [Abstract][Full Text] [Related]
19. The ability of the American Joint Committee on Cancer Staging system to predict progression-free survival after radical prostatectomy.
May F; Hartung R; Breul J
BJU Int; 2001 Nov; 88(7):702-7. PubMed ID: 11890240
[TBL] [Abstract][Full Text] [Related]
20. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
